140 related articles for article (PubMed ID: 21214085)
1. Drug may protect children's hearts from chemotherapy.
McBride D
ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
[No Abstract] [Full Text] [Related]
2. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
3. Doxorubicin-induced myocardial injury.
Fujisaki G; Inokuchi C; Murashige N
N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
[No Abstract] [Full Text] [Related]
4. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
5. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
6. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
7. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum RH
Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
[No Abstract] [Full Text] [Related]
8. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
9. Doxorubicin-induced cardiomyopathy.
Muggia FM; Speyer JL
N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
[No Abstract] [Full Text] [Related]
10. Doxorubicin-induced cardiomyopathy.
Swain SM
N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
[No Abstract] [Full Text] [Related]
11. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
12. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
13. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
Kolygin BA
Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558
[No Abstract] [Full Text] [Related]
14. [Chemotherapy-induced cardiac toxicity and management].
Komagata H; Sakai H
Gan To Kagaku Ryoho; 2003 Jun; 30(6):787-92. PubMed ID: 12852345
[TBL] [Abstract][Full Text] [Related]
15. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Gershanovich ML
Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530
[No Abstract] [Full Text] [Related]
16. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity and cardioprotection in breast cancer chemotherapy. The role of dexrazoxane.
Venturini M
Clin Ter; 1998; 149(921):5-6. PubMed ID: 9621480
[No Abstract] [Full Text] [Related]
18. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
19. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Lipshultz SE
J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739
[No Abstract] [Full Text] [Related]
[Next] [New Search]
